Belite Bio reported positive topline Phase III DRAGON data: oral tinlarebant met the primary endpoint by reducing the growth rate of retinal lesions in Stargardt disease type 1. The company said the result clears a path toward regulatory filings in multiple jurisdictions, including a planned US submission next year. Tinlarebant lowers serum retinol binding protein 4 to reduce toxic vitamin A derivatives that accumulate in the retina. The trial enrolled adolescents and showed a statistically significant and clinically meaningful reduction versus placebo. Belite plans to move rapidly to regulatory engagement and commercialization planning for what would be the first approved therapy for STGD1, a rare genetic macular dystrophy with no current treatments.